Expertise in
2
conditions

Dongmei M. Yan

Xuzhou, CN 
Expertise in
2
conditions
Xuzhou, CN 

Overview

Dongmei Yan practices practicing medicine in Xuzhou, China.

Yan is highly rated in 2 conditions, according to our data. Their clinical expertise encompasses Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Non-Hodgkin Lymphoma, Hemophagocytic Lymphohistiocytosis, and Bone Marrow Transplant.

They are actively involved in clinical research, co-authoring 58 peer reviewed articles and participating in 1 clinical trial.

Locations

Xuzhou, China
Other Locations
Yancheng, China
Shanghai Key Lab Of Chemical Biology, Shanghai, China
Hangzhou, China
MoE Key Laboratory For Biomedical Photonics, Wuhan, 430074, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Ibrutinib
Study Phase: Phase 3

58 Total Publications

Long-term follow-up of third generation anti-CD30 CAR T-cell therapy in relapsed/refractory CD30+ lymphomas: a single-arm, multicentre, phase 1-2 trial.
Long-term follow-up of third generation anti-CD30 CAR T-cell therapy in relapsed/refractory CD30+ lymphomas: a single-arm, multicentre, phase 1-2 trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 06, 2026

Frequently Asked Questions about Dongmei M. Yan

Is Dongmei M. Yan a top-rated expert for Diffuse Large B-Cell Lymphoma (DLBCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dongmei M. Yan is classified as an Advanced expert for Diffuse Large B-Cell Lymphoma (DLBCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Dongmei M. Yan participate in research or clinical trials?

Yes. Dongmei M. Yan has published 58 articles and abstracts on conditions like Diffuse Large B-Cell Lymphoma (DLBCL). You can view a list of Dongmei M. Yan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Yan's expertise for a condition
ConditionClose
      View All 20 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile